Roche's Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer

Tecentriq is a monoclonal antibody that binds with the PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells. It blocks interactions with both PD-1 and B7.1 receptors.